Vitafoods Europe 2025 live: HTBA unveils clinical research on bioidentical vitamin B12 for cognition and performance
21 May 2025 | HTBA
Unveiled at the ongoing Vitafoods Europe 2025, Tom D’hoore, HTBA’s chief commercial officer, and Teresa Pellicer, Ph.D., the company’s project manager of biotechnology, present new clinical research on the benefits of MecobalActive for cognition and physical performance. A clinical study involving healthy, active individuals taking HTBA’s proprietary methylcobalamin ingredient, a bioidentical form of vitamin B12, found that MecobalActive increased physical power, reduced fatigue, and enhanced cognitive response compared to a placebo. D’hoore and Pellicer also explore MecobalActive’s production and consumer trends related to brain health and active nutrition.
Upcoming webinars
The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis
From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot
Texture challenges in high protein bars: Understanding the benefits of casein
Lactalis Ingredients
